Section 52
Chapter 51,711

Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials

Gray, S.W.; Hlubocky, F.J.; Ratain, M.J.; Daugherty, C.K.

Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology 25(23): 3488-3494


ISSN/ISBN: 0732-183X
PMID: 17687154
DOI: 10.1200/jco.2007.11.7283
Accession: 051710848

Download citation:  

Although both financial and intrinsic conflicts of interest can exist throughout the drug development process, little is known about how advanced cancer patients enrolled onto early phase clinical trials perceive investigator conflicts of interests. We interviewed 102 advanced cancer patients enrolled onto phase I clinical trials using a standardized survey that addressed multiple issues related to conflicts of interest and research participation. Fifty-five percent of patients would not be concerned if physicians involved in running a clinical trial had financial conflicts of interest, whereas 65% of patients would be concerned if physicians involved in running a trial had intrinsic conflicts of interest. Most patients reported that potential conflicts of interest should be disclosed to patients on research trials (52% for financial conflicts of interest and 61% for more intrinsic conflicts of interest). Most patients would be willing to participate in trials after learning conflict of interest information (63%). Younger patients expressed more concern regarding financial conflict of interest than older patients (odds ratio, 6.22; 95% CI, 1.41 to 27.24). Patients with advanced cancer are equally, if not more, concerned about traditional intrinsic conflicts of interest as compared with financial conflicts of interest. Patients generally believed that conflict of interest information should be disclosed to research participants. The fact that younger patients expressed more concern about financial conflicts of interest may have the potential to influence clinical trial participation rates. The actual impact of conflict of interest disclosure to research subjects needs to be evaluated more carefully.

PDF emailed within 0-6 h: $19.90